Komori
Other Disclosures4888STELLA PHARMA CORPORATIONPharmaceuticals

Notice regarding the scheduled review of Steboronin by the Pharmaceutical Affairs Council for cutaneous angiosarcoma

It was announced that the application to add an indication for Steboronin for cutaneous angiosarcoma is scheduled to be reviewed by the Second Subcommittee on Drugs of the Pharmaceutical Affairs Council on 30 November 2026. Whether approval will be granted and the final indication and efficacy will be determined through future review and regulatory procedures.

Worth reading
71In focus
0–100. This measures how worthwhile something is to read, not how good or bad the company is.
Direction
Neutral
Direction inferred from the company’s description.
Scale
50
Response rate (within 90 days, 90% confidence interval: 22.2%–77.8%)
Wording
Avoiding a definitive answer
How definitive the wording is.

No category-specific facts could be extracted from this document.

The reasons the company gives

The company's own explanation, not something inferred from the numbers.

The Ministry of Health, Labour and Welfare announced that it will review the application at the Second Subcommittee on Drugs of the Pharmaceutical Affairs Council, scheduled to meet on 30 November 2026. The application is based on the results of the domestic Phase II study (JAM002 study).

How to read this page

This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.
Notice regarding the scheduled review of Steboronin by the Pharmaceutical Affairs Council for cutaneous angiosarcoma | STELLA PHARMA CORPORATION (4888) timely disclosure | Komori